Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PHAR vs VTYX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PHAR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

PHAR Overall Winner 6-Pillar Tally: PHAR 5 – 1 VTYX Matrix Metrics: PHAR 5 – 4 VTYX

As of Nov 16, 2026, Pharming Group N.V. ADS, each representing 10 (PHAR) is the stronger overall head-to-head candidate over Ventyx Biosciences, Inc. (VTYX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PHAR carries a Unified Composite Score of 36.2/100 (SELL) at $12.59 (N/M Forward P/E, 12.8% operating margin), whereas VTYX carries 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VTYX currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. PHAR 36.2/100 SELL), PHAR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.8% vs. 0.0% operating margin) and revenue trajectory (+20.8% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PHAR vs VTYX
PHAR NASDAQ Head-to-Head Winner
Pharming Group N.V. ADS, each representing 10 ordinary shares
Pharmaceutical Preparations
$12.59
-0.08% 1D
Market Cap $891.8M
TTM Revenue $387M
Forward P/E N/M
Beta / 30D Vol 0.82β · 60% Vol
Unified Composite Score
36.2 / 100 SELL
Tech 27.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.6% over 20 days), RSI 58
RSI-14: 58.1 · SMA20: $12.11 · SMA50: $10.98
VTYX NASDAQ
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72

6-Pillar Scorecard Institutional Category Breakdown (PHAR 5 – 1 VTYX)

Columns: Metric · PHAR · VTYX
1. Valuation Multiples PHAR
Forward P/E N/M N/M
Trailing P/E 39.4x N/M
PEG Ratio N/M N/M
EV / Revenue 2.3x N/M
2. Growth & Scale PHAR
Revenue Growth (YoY) +20.8% +0.0%
Earnings Growth (YoY) +74.9% +0.0%
TTM Revenue (USD) $387M N/A
Market Cap $891.8M $1.0B
3. Profitability & Quality PHAR
Gross Margin 87.7% N/A
Operating Margin 12.8% 0.0%
Net Profit Margin 6.2% 0.0%
Return on Equity (ROE) 8.7% -45.4%
4. Balance Sheet & Cash Flow PHAR
Cash Generation (TTM) $57M EBITDA N/A
Cash Flow Margin 14.7% EBITDA Mgn N/A
Net Cash / Leverage $4.26 Book/Sh · 8.7% ROE $2.68 Book/Sh · -45.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTYX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.5% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat PHAR
OpEx & R&D Intensity 74.9% of Rev ($290M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PHAR (5) vs VTYX (4)
Institutional Metric PHAR VTYX Criterion Row Edge
Market Capitalization
Scale
$891.8M $1.0B Larger Scale VTYX
Trailing P/E Ratio
Valuation
39.4x N/M Lower Multiple PHAR
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+20.8% +0.0% Higher Growth PHAR
Operating Margin (TTM)
Profitability
12.8% 0.0% Higher Margin PHAR
Net Profit Margin
Profitability
6.2% 0.0% Higher Margin PHAR
Return on Equity (ROE)
Capital Efficiency
8.7% -45.4% Higher ROE PHAR
52-Week Range Position
Momentum
28% ($9–$21) 55% ($1–$25) Stronger Trend VTYX
Beta / 30D Volatility
Risk Regime
0.82β · 60% Vol 2.07β · 2% Vol Lower Realized Risk VTYX
Unified Institutional Score
Composite Signal
36.2 / 100 (SELL) 50.4 / 100 (HOLD) Higher Composite VTYX
Trailing 12M Revenue (USD)
Operating Scale
$387M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$57M EBITDA ($4.26 Book/Sh · 8.7% ROE) N/A ($2.68 Book/Sh · -45.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTYX +25.13 pp
PHAR: -24.77% · VTYX: +0.36%
3M Horizon VTYX +52.0 pp
PHAR: -12.0% · VTYX: +40.0%
6M Horizon VTYX +59.2 pp
PHAR: -12.6% · VTYX: +46.6%
1Y Horizon VTYX +59.2 pp
PHAR: -12.6% · VTYX: +46.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PHAR vs VTYX. Trailing 12-month operating profitability (PHAR 12.8% vs VTYX 0.0%) and valuation multiples (PHAR N/M vs VTYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PHAR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$387M
Gross Margin87.7%
Op. Margin12.8%
ROE / Fwd P/E8.7% · N/M
VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PHAR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PHAR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PHAR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $891.8M market capitalization and 12.8% operating margin.
OpEx & R&D Reinvestment 74.9% of Rev ($290M)
90D Engineering Disclosures 0 Published
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PHAR vs VTYX Key Questions & Quantitative Answers

As of Nov 16, 2026, Pharming Group N.V. ADS, each representing 10 (PHAR) is the stronger overall head-to-head candidate over Ventyx Biosciences, Inc. (VTYX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PHAR carries a Unified Composite Score of 36.2/100 (SELL) at $12.59 (N/M Forward P/E, 12.8% operating margin), whereas VTYX carries 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VTYX currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. PHAR 36.2/100 SELL), PHAR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.8% vs. 0.0% operating margin) and revenue trajectory (+20.8% vs. +0.0% YoY).

PHAR leads the Growth & Scale pillar: PHAR posts +20.8% YoY revenue growth and +74.9% YoY earnings growth on $387M TTM revenue (87.7% gross margin, 12.8% operating margin), compared with VTYX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PHAR generates $387M in USD-normalized revenue versus N/A for VTYX. In operating R&D and SG&A reinvestment, PHAR deploys 74.9% of Rev ($290M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTYX.

PHAR screens cheaper on headline valuation multiples. PHAR trades at N/M Forward P/E, 39.4x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (14.7% EBITDA margin), whereas VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PHAR (8.7% ROE) versus VTYX (-45.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PHAR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.82β · 60% Vol realized risk). By comparison, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.